Merck & Company, Inc. (MRK) Stock: Surges 12% on Moderna Cancer Trial Win
TLDR
-
Merck stock jumps 12.12% after a major Phase 3 melanoma treatment trial win.
-
Merck and Moderna report positive Phase 3 results for their melanoma therapy.
-
Intismeran plus KEYTRUDA improves recurrence-free survival in melanoma patients.
-
Phase 3 results mark a major milestone for personalized mRNA cancer treatment.
-
Merck and Moderna plan to share the melanoma trial results with regulators.
Merck & Company, Inc. (MRK) stock surged 12.12% to $151.56 on Wednesday following positive Phase 3 melanoma trial results. Shares extended their rally after rising sharply from an intraday level near $135.17. The results strengthened Merck’s cancer pipeline as its collaboration with Moderna reached an important clinical milestone.
Merck Stock Jumps After Phase 3 Melanoma Success
Merck and Moderna reported positive topline results from the Phase 3 INTerpath-001 clinical trial. The study evaluated intismeran autogene alongside Merck’s KEYTRUDA treatment in patients with surgically removed melanoma. Importantly, the trial met its primary endpoint for recurrence-free survival.
… Continue reading the full article at the original source below.
